Journal of the American Society of Nephrology, Vol 7, 2654-2657, Copyright © 1996 by American Society of Nephrology

REGULAR ARTICLES

The evaluation of iron status in hemodialysis patients

S Fishbane, EA Kowalski, LJ Imbriano and JK Maesaka
Winthrop-University Hospital, Mineola, NY, USA.

Effective treatment of anemia in hemodialysis patients requires ongoing monitoring of iron status. The purpose of this study was to determine levels of commonly used iron indices predictive of iron deficiency in this population. Forty-seven patients with baseline serum ferritin levels < 600 ng/mL were treated with intravenous iron dextran (INFeD; Schein Pharmaceutical Inc., Florham Park, NJ), 1000 mg over ten hemodialysis treatments. Patients whose hematocrit value increased by 5% or who had a 10% decrease in their erythropoietin dose by 2 months were classified as having iron deficiency (N = 31; 66%). All other subjects were classified as having adequate iron (N = 16; 34%). There was no statistically significant difference in baseline serum ferritin, transferrin saturation, mean cell volume, mean cell hemoglobin content, or red cell distribution width between the two groups. Receiver operator curves demonstrated that none of the iron indices had a high level of utility (both sensitivity and specificity > 80%). Two tests had marginal utility, serum ferritin at a level of < 150 ng/mL, and transferrin saturation < 21%. It was concluded that because of the tests' marginal utility, they should only be interpreted in the context of the patient's underlying erythropoietin, responsiveness. In patients who are responsive to erythropoietin, a transferrin saturation value < 18% or serum ferritin level < 100 ng/mL should be used to indicate inadequate iron. When erythropoietin resistance is present, transferrin saturation of < 27% or serum ferritin < 300 ng/mL should be used to guide iron management.

This article has been cited by other articles:

				K.-L. Kuo, S.-C. Hung, Y.-H. Wei, and D.-C. Tarng Intravenous Iron Exacerbates Oxidative DNA Damage in Peripheral Blood Lymphocytes in Chronic Hemodialysis Patients J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1817 - 1826. [Abstract] [Full Text] [PDF]

				D. W. Coyne, T. Kapoian, W. Suki, A. K. Singh, J. E. Moran, N. V. Dahl, A. R. Rizkala, and the DRIVE Study Group Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study J. Am. Soc. Nephrol., March 1, 2007; 18(3): 975 - 984. [Abstract] [Full Text] [PDF]

				W. H. Horl Clinical Aspects of Iron Use in the Anemia of Kidney Disease J. Am. Soc. Nephrol., February 1, 2007; 18(2): 382 - 393. [Full Text] [PDF]

				D. W. Coyne Practice Recommendations Based on Low, Very Low, and Missing Evidence Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 11 - 12. [Full Text] [PDF]

				J. B. Wish Assessing Iron Status: Beyond Serum Ferritin and Transferrin Saturation Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(Supplement_1): S4 - S8. [Abstract] [Full Text] [PDF]

				B. A. J. Walters and D. B. Van Wyck Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1438 - 1442. [Abstract] [Full Text] [PDF]

				G. R. Aronoff Safety of Intravenous Iron in Clinical Practice: Implications for Anemia Management Protocols J. Am. Soc. Nephrol., December 1, 2004; 15(suppl_2): S99 - S106. [Full Text] [PDF]

				B. Scheiber-Mojdehkar, B. Lutzky, R. Schaufler, B. Sturm, and H. Goldenberg Non-Transferrin-Bound Iron in the Serum of Hemodialysis Patients Who Receive Ferric Saccharate: No Correlation to Peroxide Generation J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1648 - 1655. [Abstract] [Full Text] [PDF]

				K. S. Brimble, C. G. Rabbat, P. McKenna, K. Lambert, and E. J. Carlisle Protocolized Anemia Management with Erythropoietin in Hemodialysis Patients: A Randomized Controlled Trial J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2654 - 2661. [Abstract] [Full Text] [PDF]

				C.-L. Chuang, R.-S. Liu, Y.-H. Wei, T.-P. Huang, and D.-C. Tarng Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients Nephrol. Dial. Transplant., February 1, 2003; 18(2): 370 - 377. [Abstract] [Full Text] [PDF]

				N. Tessitore, G. P. Solero, G. Lippi, A. Bassi, G. B. Faccini, V. Bedogna, L. Gammaro, G. Brocco, G. Restivo, P. Bernich, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin Nephrol. Dial. Transplant., July 1, 2001; 16(7): 1416 - 1423. [Abstract] [Full Text] [PDF]

				J. Parkkinen, L. von Bonsdorff, S. Peltonen, C. Gronhagen-Riska, and K. Rosenlof Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration Nephrol. Dial. Transplant., November 1, 2000; 15(11): 1827 - 1834. [Abstract] [Full Text] [PDF]

				A. BESARAB, N. AMIN, M. AHSAN, S. E. VOGEL, G. ZAZUWA, S. FRINAK, J. J. ZAZRA, J. V. ANANDAN, and A. GUPTA Optimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients J. Am. Soc. Nephrol., March 1, 2000; 11(3): 530 - 538. [Abstract] [Full Text] [PDF]

				A. BESARAB, S. FRINAK, and J. YEE An Indistinct Balance: The Safety and Efficacy of Parenteral IronTherapy J. Am. Soc. Nephrol., September 1, 1999; 10(9): 2029 - 2043. [Full Text]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673